Branko Cuglievan

Branko Cuglievan is a Senior Professor at The University of Texas MD Anderson Cancer Center. His research focuses on hematological malignancies, specifically leukemia and pediatrics, with a current emphasis on menin inhibitor resistance in acute myeloid leukemia (AML) and immunophenotypic changes following targeted therapy. He has published extensively on combination therapies involving BET proteins and BRG1/BRM inhibitors for high-risk AML, as well as long-term survival outcomes in blastic plasmacytoid dendritic cell neoplasm (BPDCN). His work also addresses immune-related toxicity in hematopoietic stem cell transplantation and differentiation syndrome proteomic profiling.